FDA Approves Durvalumab For Limited-Stage Small Cell Lung Cancer; Recommended Durvalumab Dose Is 1,500 MG Every 4 Weeks For Patients With A Body Weight Of ≥30 KG; Approved Astrazeneca's Imfinzi For Adults With LS-SCLC Whose Disease Has Not Progressed...
FDA Approves Durvalumab For Limited-Stage Small Cell Lung Cancer; Recommended Durvalumab Dose Is 1,500 MG Every 4 Weeks For Patients With A Body Weight Of ≥30 KG; Approved Astrazeneca's Imfinzi For Adults With LS-SCLC Whose Disease Has Not Progressed...
FDA批准Durvalumab用於有限期小細胞肺癌；建議Durvalumab劑量爲每4周1500毫克，適用於體重≥30千克的患者；批准阿斯利康的Imfinzi用於病情未進展的成人LS-SCLC...
FDA Approves Durvalumab For Limited-Stage Small Cell Lung Cancer; Recommended Durvalumab Dose Is 1,500 MG Every 4 Weeks For Patients With A Body Weight Of ≥30 KG; Approved Astrazeneca's Imfinzi For Adults With LS-SCLC Whose Disease Has Not Progressed Post Platinum-Based Chemotherapy & Radiation Therapy
FDA批准了杜瓦利尤單抗用於有限期小細胞肺癌；推薦的杜瓦利尤單抗劑量爲每4周1,500毫克，適用於體重≥30公斤的患者；批准阿斯利康的伊姆芬齊用於經過鉑金類化療和放射治療後病情未進展的LS-SCLC成年患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。